UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

	-	egistrant ⊠ ty other than the Registrant □	
	the app Pre Co De De	propriate box: eliminary Proxy Statement infidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ifinitive Proxy Statement ifinitive Additional Materials liciting Material Pursuant to § 240.14a-12	
		Biocept, Inc. (Exact name of registrant as specified in its charter)	
		(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)	
Payme	ent of Fi	ling Fee (Check the appropriate box)	
\boxtimes	No fe	e required.	
	Fee c	omputed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
	1.	Title of each class of securities to which transaction applies:	
	2.	Aggregate number of securities to which transaction applies:	
	3.	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):	
	4.	Proposed maximum aggregate value of transaction:	
	5.	Total fee paid:	
	Fee p	e paid previously with preliminary materials.	
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.		
	6.	Amount Previously Paid:	
	7.	Form, Schedule or Registration Statement No.:	
	8.	Filing Party:	
	9.	Date Filed:	

EXPLANATORY NOTE

Subsequent to the filing of its definitive proxy statement with the Securities and Exchange Commission on April 30, 2015 (the "*Proxy Statement*"), Biocept, Inc. (the "*Company*") hired Regan & Associates, Inc. to provide proxy solicitation and advisory services related to the proposals set forth in the Proxy Statement. Regan & Associates, Inc. will be paid approximately \$27,500 plus out-of-pocket expenses in connection with its solicitation of proxies on behalf of the Company.